SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape

Abstract

The 501Y.V2 variants of SARS-CoV-2 containing multiple mutations in spike are now dominant in South Africa and are rapidly spreading to other countries. Here, experiments with 18 pseudotyped viruses showed that the 501Y.V2 variants do not confer increased infectivity in multiple cell types except for murine ACE2-overexpressing cells, where a substantial increase in infectivity was observed. Notably, the susceptibility of the 501Y.V2 variants to 12 of 17 neutralizing monoclonal antibodies was substantially diminished, and the neutralization ability of the sera from convalescent patients and immunized mice was also reduced for these variants. The neutralization resistance was mainly caused by E484K and N501Y mutations in the receptor-binding domain of spike. The enhanced infectivity in murine ACE2-overexpressing cells suggests the possibility of spillover of the 501Y.V2 variants to mice. Moreover, the neutralization resistance we detected for the 501Y.V2 variants suggests the potential for compromised efficacy of monoclonal antibodies and vaccines.

Cited by papers we hold 14

• Emergence of a novel SARS-CoV-2 Pango lineage B.1.1.526 in West Bengal, India · 2022
  Not checked
• SARS-CoV-2 Omicron variant: recent progress and future perspectives · 2022
  No notice
• SARS-COV-2 Variants: Differences and Potential of Immune Evasion · 2022
  No notice
• A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations · 2022
  No notice
• Omicron SARS-CoV-2 mutations stabilize spike up-RBD conformation and lead to a non-RBM-binding monoclonal antibody escape · 2022
  No notice
• COVID-19 vaccine development: milestones, lessons and prospects · 2022
  No notice
• Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay · 2022
  No notice
• The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines · 2022
  No notice
• Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis · 2022
  No notice
• Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity · 2021
  Not checked
• Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines · 2021
  No notice
• The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron · 2021
  No notice
• Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far? · 2021
  No notice
• Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.